Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
No aliases recorded.
Eflornithine, sold under the brand name Ornidyl among others, is a medication used to treat African trypanosomiasis (sleeping sickness) and excessive hair growth on the face in women. Specifically it is used for the second stage of sleeping sickness caused by T. b. gambiense and may be used with nifurtimox. It is taken intravenously (injection into a vein) or topically. It is an ornithine decarboxylase inhibitor.
Read the full article on WikipediaHigh-risk neuroblastoma Clinical criteria: Treatment Phase: Initial treatment Patient must have high-risk neuroblastoma according to a validated risk classification system, AND Patient must be in remission, with at least a partial response, at the end of multiagent, multimodality therapy for high-risk neuroblastoma, AND The treatment must be initiated after completing previous therapy, AND Patient must not have previously received PBS-subsidised treatment with this drug for this condition. Treatment criteria: Must be treated in a hospital/cancer centre by either a: (i) paediatric oncologist, (ii) haematologist. Prior to initiating treatment with this drug, a complete blood count, liver function tests and baseline hearing assessments should be performed and documented in the patient's medical records. At the time of the authority application, the prescriber should request an appropriate quantity and number of repeats based on the patient's Body Surface Area (BSA), according to the dosing schedule in the TGA approved Product Information. The following maximum quantity units and repeats may be authorised under this restriction (providing 3 months of therapy for each prescription). Up to a maximum quantity of 100 units and 1 repeat for a BSA 0.25 m2 to less than 0.5 m2; Up to a maximum quantity of 200 units and 1 repeat for a BSA 0.5 m2 to less than 0.75 m2; Up to a maximum quantity of 200 units and 2 repeats for a BSA 0.75 m2 to 1.5 m2; Up to a maximum quantity of 300 units and 2 repeats for a BSA greater than 1.5 m2. Authority applications for initial treatment must be made in writing and must include: (a) details of the proposed prescription; and (b) a completed PBS authority application form, relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes the following: (i) details of prior multiagent, multimodality therapy for high-risk neuroblastoma [date of commencement and duration of therapy]; and (ii) the patient's BSA measurement.
“8 hours”
Working under the parallel aged-care framework? Aged-care equivalent →